CLINICAL_TRIALS
trial_result
· 2016-01-11
Clinical Trial Update: Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205 [Phase 2]
Summary
This is a Phase 2 trial update for single-agent erlotinib in ependymoma patients previously treated with oral etoposide (OSI-774-205); the study is terminated a…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: OSI Pharmaceuticals | Conditions: Ependymoma | Phase 2 | Status: TERMINATED | Results posted: 2016-01-11